Skip to content

The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty

The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06489626
Enrollment
0
Registered
2024-07-08
Start date
2025-11-01
Completion date
2027-12-01
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis Knee, Knee Osteoarthritis, Pain, Postoperative

Keywords

total knee arthroplasty, knee osteoarthritis, pain management

Brief summary

Pain control and early range of motion following total knee arthroplasty are essential for patient satisfaction. Intraoperative steroids (dexamethasone) have been shown to have a significant effect in controlling acute pain following total knee arthroplasty. This study aims to evaluate the effect of a post-operative steroid (methylprednisolone) taper in improving functional and patient-reported outcomes following total knee arthroplasty. A taper means taking a high dose of a medication followed by taking lower doses and each following day until the medication is stopped.

Interventions

DRUGMethylprednisolone 4 milligram Tab

6-day 4 milligram methylprednisolone oral taper

4 milligram intravenous dexamethasone will be administered intraoperatively

Sponsors

F. Johannes Plate
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients indicated for primary total knee arthroplasty. * Access to computer or smartphone for completion of REDCap surveys

Exclusion criteria

* Patients less than 18 years of age, patients unable to consent, known diabetic patients and those with an HgbA1c \>6.5 preoperatively, patients who are on chronic steroid treatments, patients with chronic pain on opioid management, patients with allergies to steroids, patients with a history of peptic ulcer disease, patients with a history of heart failure and patients with a history of renal and/or hepatic failure will be excluded. Those that are immunosuppressed as well as pregnant and/or lactating will also be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Daily Pain at rest and with movementdaily for two weeksnumeric rating scale from 0 to 10 (0=minimal, 10=maximal) will be used to capture patient experienced pain
Prescription narcotic usagedaily for two weeksOral morphine equivalent units will be collected based on patient usage of prescribed narcotic pain medication
Sleep disturbancedaily for two weeksPatients will be asked if pain caused them to be awoken in the night and if so what level of pain they were experiencing at that time
Knee Range of motion2-week, 6-week and 3-month postoperative visitsgoniometric measurement of knee extension and flexion

Secondary

MeasureTime frameDescription
Wound healing2-week, 6-week and 3-month postoperative visitsSurgical site will be evaluated for normal wound healing
Knee Injury and Osteoarthritis Outcome Scores2-week, 6-week and 3-month postoperative visitsQuestionnaire assessing for function will be administered (0= extreme problems present, 100= no problems present)

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJohannes F Plate

University of Pittsburgh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026